StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRSPBullishAnalyst Target Updateanalyst
Medium materiality6/10

Piper Sandler Reiterates Overweight Rating on CRISPR Therapeutics (CRSP)

Nov 10, 2026, 12:10 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Bullish analyst stance and a large target-to-price gap support a positive view, though the reiteration itself is not a new upgrade.

AI summary

What happened, with direct paths to the underlying reporting

Piper Sandler reiterated an Overweight rating with a $110 target versus the posted price of $48.21, indicating substantial analyst-identified upside. This is an analyst view, not a guarantee of performance.

  • $110 target vs. $48.21 posted price
  • Overweight rating reiterated by Piper Sandler

Key facts

  1. 01

    Target: $110

  2. 02

    Posted price: $48.21

  3. 03

    Analyst firm: Piper Sandler

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.